What have we learnt about high-density lipoprotein cholesterol measurements during 32 years? Experiences in Finland 1980-2012

Clinica Chimica Acta

Volumn 415, Issue , 2013, Pages 118-123

  Leiviskä, Jaana ^a   Sundvall, Jouko ^a   Alfthan, Georg ^a   Tähtelä, Riitta ^b   Salomaa, Veikko ^a   Jauhiainen, Matti ^a,c   Vartiainen, Erkki ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b Mehiläinen Sports Hospital   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Apolipoprotein A I; Cardiovascular disease; External quality assessment; High density lipoprotein cholesterol; Metabolic syndrome

Indexed keywords

APOLIPOPROTEIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ACCURACY; ADULT; AGED; ARTICLE; CALIBRATION; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; FINLAND; HUMAN; INTERMETHOD COMPARISON; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; QUALITY CONTROL; RELIABILITY; SEX DIFFERENCE; STEROL ANALYSIS;

ADULT; AGED; APOLIPOPROTEIN A-I; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; ENZYME ASSAYS; FEMALE; FINLAND; HEALTH SURVEYS; HUMANS; IMMUNOASSAY; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; QUALITY CONTROL; RISK;

EID: 84868243649     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.10.027     Document Type: Article

References (31)

1. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707-714.
2. Catapano A.L., Reiner Z., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46.
3. Lewis G.F., Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005, 96:1221-1232.
4. Gordon S.M., Hofmann S., Askew D.S., Davidson W.S. High density lipoprotein: it's not just about lipid transport anymore. Trends Endocrinol Metab 2011, 22:9-15.
5. Movva R., Rader D.J. Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008, 54:788-800.
6. Mahley R.W., Innerarity T.L., Rall S.C., Weisgraber K.H. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984, 25:1277-1294.
7. Elsoe S., Ahnström J., Christoffersen C., Hoofnagle A.N., Plomgaard P., Heinecke J.W., et al. Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. Atherosclerosis 2012, 221:91-97.
8. Scanu A.M., Edelstein C. HDL: bridging past and present with a look at the future. FASEB J 2008, 22:4044-4054.
9. Austin M.A., King M.C., Vranizan K.M., Krauss R.M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495-506.
10. Warnick G.R., Nauck M., Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem 2001, 47:1579-1596.
11. Miller W.G., Myers G.L., Sakurabayashi I., Bachmann L.M., Caudill S.P., Dziekonski A., et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem 2010, 56:977-986.
12. Warnick G.R., Wood P.D. National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 1995, 41:1427-1433.
13. Sundvall J., Leiviskä J., Alfthan G., Vartiainen E. Serum cholesterol during 27 years: assessment of systematic error and affecting factors and their role in interpreting population trends. Clin Chim Acta 2007, 378:93-98.
14. Langlois M.R., Blaton V.H. Historical milestones in measurement of HDL-cholesterol: impact on clinical and laboratory practice. Clin Chim Acta 2006, 369:168-178.
15. Vartiainen E., Laatikainen T., Peltonen M., Juolevi A., Männistö S., Sundvall J., et al. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010, 39:504-518.
16. Leiviskä J., Sundvall J., Alfthan G., Jauhiainen M., Salomaa V. Apolipoprotein A-I, apolipoprotein B, and apolipoprotein B/apolipoprotein A-I ratio: reference intervals compared with values in different pathophysiological conditions from the FINRISK 2007 study. Clin Chim Acta 2011, 412:1146-1150.
17. Finley P.R., Schifman R.B., Williams R.J., Lichti D.A. Cholesterol in high-density lipoprotein: use of Mg2+/dextran sulfate in its enzymic measurement. Clin Chem 1978, 24:931-933.
18. Sugiuchi H., Uji Y., Okabe H., Irie T., Uekama K., Kayahara N., et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem 1995, 41:717-723.
19. Nauck M., März W., Wieland H. New immunoseparation-based homogeneous assay for HDL-cholesterol compared with three homogeneous and two heterogeneous methods for HDL-cholesterol. Clin Chem 1998, 44:1443-1451.
20. Rifai N., Cole T.G., Iannotti E., Law T., Macke M., Miller R., et al. Assessment of interlaboratory performance in external proficiency testing programs with a direct HDL-cholesterol assay. Clin Chem 1998, 44:1452-1458.
21. Sim J., Wright C.C. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther 2005, 85:257-268.
22. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
23. Agrawal M., Spencer H.J., Faas F.H. Method of LDL cholesterol measurement influences classification of LDL cholesterol treatment goals: clinical research study. J Investig Med 2010, 58:945-949.
24. Salomaa V.V., Jauhiainen M., Pietinen P., Korhonen H.J., Kartovaara L., Vartiainen E., et al. Five-year trend in serum HDL-lipoprotein cholesterol in the Finnish population aged 25-64years. A suggestion of an increase. Atherosclerosis 1991, 86:39-48.
25. Ingelsson E., Massaro J.M., Sutherland P., Jacques P.F., Levy D., D'Agostino R.B., et al. Contemporary trends in dyslipidemia in the Framingham Heart Study. Arch Intern Med 2009, 169:279-286.
26. Arnett D.K., Jacobs D.R., Luepker R.V., Blackburn H., Armstrong C., Claas S.A. Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980-1982 to 2000-2002. Circulation 2005, 112:3884-3891.
27. Gibson J.C., Rubinstein A., Brown W.V. Precipitation of apo E-containing lipoproteins by precipitation reagents for apolipoprotein B. Clin Chem 1984, 30:1784-1788.
28. Contois J.H., Warnick G.R., Sniderman A.D. Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. J Clin Lipidol 2011, 5:264-272.
29. Sniderman A.D., Williams K., Contois J.H., Monroe H.M., McQueen M.J., de Graaf J., et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011, 4:337-345.
30. Walldius G., Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Int Med 2006, 259:493-519.
31. Di Angelantonio E., Sarwar N., Perry P., Kaptoge S., Ray K.K., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000. Emerging Risk Factors Collaboration,.